OmniAb, Inc. (NASDAQ:OABI)
| Market Cap | 740.04M+243.9% |
| Revenue (ttm) | 40.18M+90.5% |
| Net Income | -43.47M+31.7% |
| EPS | -0.34+41.4% |
| Shares Out | 145.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,148,655 |
| Open | 5.16 |
| Previous Close | 5.11 |
| Day's Range | 4.93 - 5.31 |
| 52-Week Range | 1.30 - 5.43 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 4.00(-21.41%) |
| Earnings Date | Mar 3, 2027 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About OABI
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Analyst consensus
3 firms rating OABI in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 3, 2027Earnings report
Ask Barron about OABI
$OABI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OABI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OABI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OABI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OABI Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| xPloration revenue | $703.00K | 69.47% |
| Cost of xPloration revenue | $309.00K | 30.53% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OABI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OABI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in OABI
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $14.22M |
| VTIVanguard Morningstar Total Stock Market ETF | $11.80M |
| VXFVanguard Extended Market ETF | $6.44M |
| IWNiShares Russell 2000 Value ETF | $5.37M |
| IBBiShares Biotechnology ETF | $4.78M |
| VTWOVanguard Russell 2000 ETF | $3.17M |
Estimated from each fund’s disclosed top holdings × AUM
OABI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from OABI’s recent data — informational, not investment advice